Recruiting
Phase 2

Trimethoprim

Sponsor:

UCLA

Code:

NCT06536374

Conditions

Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trimethoprim Tablets

Study Details

Brief summary:

The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer.

This study will help find out what effects, good and/or bad, this drug has on people who take it and on its effect on the disease. The safety of this drug in humans has been tested in prior research studies; however, some side effects may not yet be known.

Conditions

Prostate Cancer

Study ID

NCT06536374

Start date

Dec, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

INCLUSION CRITERIA

1. Provision of signed and dated informed consent form.
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Age ≥ 18 years.
4. Proven diagnosis of prostate cancer (intermediate unfavorable risk, high risk, very high risk localized per the 2025 NCCN guidelines), or metastatic hormone-sensitive prostate cancer with confirmation by pathology report and most recent prostate biopsy procedure note.
5. Prostate cancer treatment naïve.
6. Commencing androgen deprivation therapy for prostate cancer within 4 weeks of enrollment in the study. Note that radiotherapy and androgen receptor pathway inhibitors, apart from abiraterone, are allowed in both arms.
7. Hemoglobin ≥ 11 g/dL.
8. Red blood cell folate > 750 nmol/L.
9. Creatine clearance within the normal range.
10. Eastern Cooperative Oncology Group performance status 0-1
11. Stated willingness to abstain from consumption of any supplements or medications containing folic acid or potassium.
12. Ability to take oral medications and be willing to adhere to trimethoprim and androgen deprivation therapy regimens.
13. For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner.
14. Agreement to adhere to lifestyle considerations described in the protocol throughout study duration.

EXCLUSION CRITERIA

1. Current use of memantine, phenytoin, and any medications that may significantly interact with TMP, including prohibited concomitant medications listed in the protocol.
2. Current use of medications that would interfere with folate metabolism (for example, methotrexate).
3. Treatment with another investigational drug while on this study.
4. Treatment with hormone therapy, immunotherapy, chemotherapy and/or radiation therapy for any malignancies within the past 2 years. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
5. History of renal or hepatic disease, including history of hepatitis B and C.
6. Recurrent urinary tract infections, urinary retention, or neurological conditions affecting bladder function.
7. Known hypersensitivity or allergy to trimethoprim.
8. Hematological disorders (including megaloblastic anemia).
9. Commencing chemotherapy for metastatic prostate cancer.

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Trimethoprim plus androgen deprivation therapy

Administration of trimethoprim to reduce folic acid levels at the time of standard of care androgen deprivation therapy.

no intervention: Standard of Care treatment

Standard of care treatment participants will have no intervention, only their prescribed androgen deprivation therapy.

Interventions

Trimethoprim Tablets

Trimethoprim 150mg is administered once daily for 3 months

Primary outcome measure

  • Safety of Trimethoprim [ Time Frame: From first dose of study therapy through 1 month after completion of study therapy. ]

Central Contacts and Locations

Central contacts

Locations

University of California, San Diego

Recruiting

La Jolla, California, United States, 92093

Contacts

More Information

Sponsor

University of California, San Diego

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • Androgen deprivation therapy
  • Folic Acid

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.